Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients-Reference-Cited by-同舟云学术

Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients

Published:2010-03 Issue:5 Volume:46 Page:944-953
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Bignotti Eliana,Todeschini Paola,Calza Stefano,Falchetti Marcella,Ravanini Maria,Tassi Renata A.,Ravaggi Antonella,Bandiera Elisabetta,Romani Chiara,Zanotti Laura,Tognon Germana,Odicino Franco E.,Facchetti Fabio,Pecorelli Sergio,Santin Alessandro D.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Cancer statistics, 2008;Jemal;CA Cancer J Clin,2008

2. DiSaia PJ, Creasman WT, editors. Epithelial ovarian cancer. Clinical gynecologic oncology. St. Louis: Mosby – Year Book, Inc.; 2002. p .185–206.

3. Future directions in the surgical management of ovarian cancer;Berman;Gynecol Oncol,2003

4. Differential gene expression profiles between tumor biopsies and short term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy;Bignotti;Gynecol Oncol,2006

5. Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas;Fornaro;Int J Cancer,1995

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma;Gynecologic Oncology;2024-10

2. Research progress of antibody–drug conjugates in gynecologic cancer;Holistic Integrative Oncology;2024-08-29

3. Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back;Frontiers in Immunology;2024-08-15

4. Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer;Cancers;2024-07-15

5. A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response;Cell Reports Medicine;2024-05